<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138150</url>
  </required_header>
  <id_info>
    <org_study_id>GSK112035</org_study_id>
    <nct_id>NCT01138150</nct_id>
    <nct_alias>NCT00868322</nct_alias>
  </id_info>
  <brief_title>Ictal and Interictal Inflammatory Markers in Migraine</brief_title>
  <official_title>Ictal and Interictal Inflammatory Markers in Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toledo Health Science Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate blood levels of several proteins that may be altered
      in the inflammation associated with migraine headaches. These blood levels will be evaluated
      in individuals during an acute migraine attack and compared to their levels when pain free.
      The investigators study hypothesis is that the pro inflammatory proteins in the blood will be
      greater than the levels of these proteins when evaluated during a pain free period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine is a common, chronic disorder, which presents with recurrent episodes of disabling
      headache and affects approximately 12% of American adults.1,2 No biomarkers exist to identify
      episodic or chronic migraine sufferers; and the diagnosis relies solely on clinical criteria.
      Further the full pathophysiology of migraine has not been fully delineated, although our
      understanding of migraine pathophysiology has dramatically improved over the past 15 years.
      Current theories suggest that migraine is a neurovascular disorder, with the pain of migraine
      a result of the release of inflammatory neuropeptides from nerve endings in the activated
      trigeminal system (neurogenic inflammation), ultimately resulting in vasodilation, plasma
      extravasation and mast cell degranulation.3-6 Several inflammatory markers have been
      implicated in the pathway resulting in the neurogenic inflammation of migraine including
      calcitonin gene related peptide (CGRP), substance P (SP), neurokinin A, and multiple
      cytokines such as interleukin (IL) -1, IL-6 and tumor necrosis-α (TNF-α).5,7-10 More recent
      research supports that the odds of migraine are increased in those who are obese and that
      several adipose tissue derived cytokines (adipocytokines) may contribute to the neurogenic
      inflammation of migraine, including leptin and adiponectin. In one small pilot study of 33
      participants evaluating chronic and episodic migraineurs as compared to controls, adiponectin
      (an adipocytokine) was significantly elevated in chronic migraineurs as compared to controls.
      A second study reported low levels of another adipocytokine, leptin in episodic migraineurs.
      However, all of these studies have evaluated only 3 to 4 of cytokines at the same time point
      and 11 none have evaluated adipocytokines during an acute attack. We hypothesize that
      obesity-related cytokines contribute to the neurogenic inflammation of migraine and have the
      potential be useful as biomarkers for episodic and chronic migraine as well as new drug
      targets for the treatment of migraine. To this end we propose to evaluate serum levels of
      obesity-related cytokines in migraineurs, ictally (during an acute migraine attack),
      following treatment with sumatriptan/naproxen sodium (Treximet®) and interictally (at
      baseline) when pain free.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Total Serum Adiponectin (T-ADP)</measure>
    <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
    <description>Change in total serum adiponectin after treatment in responders and non responders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Molecular Weight (HMW)-Adiponectin (ADP)</measure>
    <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
    <description>serum HMW-ADP levels after treatment in responders and non responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Middle Molecular Weight (MMW)-ADP</measure>
    <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
    <description>serum MMW-ADP levels after treatment in responders and non responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Molecular Weight (LMW)-ADP</measure>
    <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
    <description>serum LMW-ADP levels after treatment in responders and non responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Molecular Weight (HMW): T-ADP</measure>
    <time_frame>30 minutes, 60 minutes, 120 minutes after treatment</time_frame>
    <description>serum HMW:T-ADP levels after treatment in responders and non responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Molecular Weight (LMW):Total (T)-ADP</measure>
    <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
    <description>serum LMW:T-ADP levels after treatment in responders and non responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
    <description>serum leptin levels after treatment in responders and non responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistin</measure>
    <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
    <description>serum resistin levels after treatment in responders and non responders</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Treximet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fourteen participants randomized to receive Treximet (sumatriptan &amp; naproxen) during an acute migraine attack. Blood drawn for immune &amp; inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet).
Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune &amp; inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo.
Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treximet</intervention_name>
    <description>One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.</description>
    <arm_group_label>Treximet</arm_group_label>
    <other_name>The brand name of sumatriptan/naproxen sodium is Treximet.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years of age, migraine

        Exclusion Criteria:

          -  Pregnant or breast-feeding women, presence of cardiovascular or cerebrovascular
             disorders as well as any known inflammatory, infectious, metabolic, thyroid, renal,
             cardiovascular or gastrointestinal diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara L Peterlin, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Bayview Headache Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <results_first_submitted>February 9, 2016</results_first_submitted>
  <results_first_submitted_qc>August 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2016</results_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine, headache, sumatriptan, naproxen sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment - December 9 2010 through January 22, 2013.
Types of location - Neurology Headache Clinic, Internal Medicine Clinics, Gynecology clinic; study flyers placed in the medical offices , Johns Hopkins Community Physicians sites, academic institutions and wellness centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Drug - Sumatriptan/Naproxen</title>
          <description>Participants randomized to sumatriptan/naproxen upon presentation of migraine acute attack</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants randomized to placebo upon presentation with acute migraine attack.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>blood unable to be processed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treximet</title>
          <description>Participants randomized to active drug Treximet during acute migraine attack.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Participants randomized to placebo (sugar pill) during acute migraine attack.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Total Serum Adiponectin (T-ADP)</title>
        <description>Change in total serum adiponectin after treatment in responders and non responders</description>
        <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders are defined as those with a reduction of pain from moderate to severe at T0 (before treatment) to none to mild 30 minutes after treatment with Treximet or sugar pill.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Treatment non-responders are defined as those without a reduction of pain from moderate to severe at T0 (before treatment) to none to mild 30 minutes after after treatment with Treximet or sugar pill.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders are defined as those with a reduction of pain from moderate to severe at T0 (before treatment) to none to mild 60 minutes after treatment with Treximet or sugar pill.</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Treatment non-responders are defined as those without a reduction of pain from moderate to severe at T0 (before treatment) to none to mild 60 minutes after treatment with Treximet or sugar pill.</description>
          </group>
          <group group_id="O5">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders are defined as those with a reduction of pain from moderate to severe at T0 (before treatment) to none to mild 120 minutes after treatment with Treximet or sugar pill.</description>
          </group>
          <group group_id="O6">
            <title>Treatment Non-Responders</title>
            <description>Treatment non-responders are defined as those without a reduction of pain from moderate to severe at T0 (before treatment) to none to mild 120 minutes after treatment with Treximet or sugar pill.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Total Serum Adiponectin (T-ADP)</title>
          <description>Change in total serum adiponectin after treatment in responders and non responders</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" lower_limit="-1.84" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-1.85" upper_limit="2.37"/>
                    <measurement group_id="O3" value="-0.97" lower_limit="-1.85" upper_limit="-0.08"/>
                    <measurement group_id="O4" value="0.29" lower_limit="-1.88" upper_limit="2.46"/>
                    <measurement group_id="O5" value="-0.98" lower_limit="-1.88" upper_limit="-0.08"/>
                    <measurement group_id="O6" value="0.24" lower_limit="-1.95" upper_limit="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Molecular Weight (HMW)-Adiponectin (ADP)</title>
        <description>serum HMW-ADP levels after treatment in responders and non responders</description>
        <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non Responders 120 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O5">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O6">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>High Molecular Weight (HMW)-Adiponectin (ADP)</title>
          <description>serum HMW-ADP levels after treatment in responders and non responders</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" lower_limit="-0.47" upper_limit="-0.01"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.76" upper_limit="0.61"/>
                    <measurement group_id="O3" value="-0.23" lower_limit="-0.46" upper_limit="-0.01"/>
                    <measurement group_id="O4" value="-0.14" lower_limit="-0.79" upper_limit="0.52"/>
                    <measurement group_id="O5" value="-0.24" lower_limit="-0.91" upper_limit="0.44"/>
                    <measurement group_id="O6" value="-0.21" lower_limit="-0.44" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Middle Molecular Weight (MMW)-ADP</title>
        <description>serum MMW-ADP levels after treatment in responders and non responders</description>
        <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non Responders 120 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O5">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O6">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Middle Molecular Weight (MMW)-ADP</title>
          <description>serum MMW-ADP levels after treatment in responders and non responders</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.25" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.19" upper_limit="0.24"/>
                    <measurement group_id="O3" value="-0.03" lower_limit="-0.26" upper_limit="0.21"/>
                    <measurement group_id="O4" value="-0.02" lower_limit="-0.23" upper_limit="0.19"/>
                    <measurement group_id="O5" value="0.16" lower_limit="-0.05" upper_limit="0.38"/>
                    <measurement group_id="O6" value="-0.03" lower_limit="-0.26" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Molecular Weight (LMW)-ADP</title>
        <description>serum LMW-ADP levels after treatment in responders and non responders</description>
        <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non Responders 120 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O5">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O6">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Low Molecular Weight (LMW)-ADP</title>
          <description>serum LMW-ADP levels after treatment in responders and non responders</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0.03" upper_limit="0.60"/>
                    <measurement group_id="O2" value="-0.43" lower_limit="-0.75" upper_limit="-0.11"/>
                    <measurement group_id="O3" value="0.15" lower_limit="-0.13" upper_limit="0.42"/>
                    <measurement group_id="O4" value="-0.25" lower_limit="-0.57" upper_limit="0.06"/>
                    <measurement group_id="O5" value="-0.45" lower_limit="-0.77" upper_limit="-0.14"/>
                    <measurement group_id="O6" value="0.11" lower_limit="-0.17" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Molecular Weight (HMW): T-ADP</title>
        <description>serum HMW:T-ADP levels after treatment in responders and non responders</description>
        <time_frame>30 minutes, 60 minutes, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non Responders 120 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O5">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O6">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>High Molecular Weight (HMW): T-ADP</title>
          <description>serum HMW:T-ADP levels after treatment in responders and non responders</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.07" upper_limit="-0.01"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.03" upper_limit="0.06"/>
                    <measurement group_id="O3" value="-0.02" lower_limit="-0.06" upper_limit="0.01"/>
                    <measurement group_id="O4" value="0.01" lower_limit="-0.04" upper_limit="0.05"/>
                    <measurement group_id="O5" value="0.01" lower_limit="-0.05" upper_limit="0.05"/>
                    <measurement group_id="O6" value="-0.02" lower_limit="-0.05" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Molecular Weight (LMW):Total (T)-ADP</title>
        <description>serum LMW:T-ADP levels after treatment in responders and non responders</description>
        <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non Responders 120 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O5">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O6">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Low Molecular Weight (LMW):Total (T)-ADP</title>
          <description>serum LMW:T-ADP levels after treatment in responders and non responders</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.01" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.07" upper_limit="-0.01"/>
                    <measurement group_id="O3" value="-0.01" lower_limit="-0.05" upper_limit="0.02"/>
                    <measurement group_id="O4" value="0.02" lower_limit="-0.02" upper_limit="0.05"/>
                    <measurement group_id="O5" value="-0.04" lower_limit="-0.07" upper_limit="-0.01"/>
                    <measurement group_id="O6" value="0.01" lower_limit="-0.02" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leptin</title>
        <description>serum leptin levels after treatment in responders and non responders</description>
        <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non Responders 120 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O5">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O6">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Leptin</title>
          <description>serum leptin levels after treatment in responders and non responders</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="-1.55" upper_limit="2.97"/>
                    <measurement group_id="O2" value="0.89" lower_limit="-0.93" upper_limit="2.71"/>
                    <measurement group_id="O3" value="0.28" lower_limit="-1.93" upper_limit="2.50"/>
                    <measurement group_id="O4" value="0.84" lower_limit="-0.91" upper_limit="2.59"/>
                    <measurement group_id="O5" value="1.00" lower_limit="-0.80" upper_limit="2.80"/>
                    <measurement group_id="O6" value="0.02" lower_limit="-2.21" upper_limit="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resistin</title>
        <description>serum resistin levels after treatment in responders and non responders</description>
        <time_frame>30 minutes after treatment, 60 minutes after treatment, 120 minutes after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Responders 120 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O2">
            <title>Treatment Non Responders 120 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Responders 30 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
          <group group_id="O4">
            <title>Treatment Non-Responders 30 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O5">
            <title>Treatment Non-Responders 60 Minutes After Treatment</title>
            <description>Participants without reduction in pain at 120 minutes after treatment</description>
          </group>
          <group group_id="O6">
            <title>Treatment Responders 60 Minutes After Treatment</title>
            <description>Treatment responders were defined as those with a reduction of pain from moderate to severe (&gt;=4/10 on the NRS) at T0 to no to mild (&lt;=3/10 on the NRS) at 120 minutes after treatment with either sumatriptan/naproxen or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Resistin</title>
          <description>serum resistin levels after treatment in responders and non responders</description>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" lower_limit="-1.83" upper_limit="-0.07"/>
                    <measurement group_id="O2" value="-0.97" lower_limit="-3.95" upper_limit="2.00"/>
                    <measurement group_id="O3" value="-1" lower_limit="-1.86" upper_limit="-0.14"/>
                    <measurement group_id="O4" value="-0.88" lower_limit="-3.75" upper_limit="1.98"/>
                    <measurement group_id="O5" value="-1.36" lower_limit="-4.30" upper_limit="1.59"/>
                    <measurement group_id="O6" value="-0.79" lower_limit="-1.65" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treximet</title>
          <description>sumatriptan/naproxen sodium: One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo: One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lee Peterlin</name_or_title>
      <organization>The Johns Hopkins University School of Medicine</organization>
      <phone>410-550-5452</phone>
      <email>lpeterlin@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

